<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic <z:e sem="disease" ids="C1332335" disease_type="Disease or Syndrome" abbrv="">arterial embolization</z:e> imparts a significant risk of serious complications throughout the lives of patients with <z:e sem="disease" ids="C0035439" disease_type="Disease or Syndrome" abbrv="rhd">rheumatic heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Left atrial (LA) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> have been thought to be the major source of emboli </plain></SENT>
<SENT sid="2" pm="."><plain>A transesophageal echocardiography (TEE) study of 260 consecutive patients with <z:e sem="disease" ids="C0264765" disease_type="Disease or Syndrome" abbrv="">rheumatic mitral valve disease</z:e> was performed during a period of 24 months, with particular reference to understanding the association between LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and embolic complications </plain></SENT>
<SENT sid="3" pm="."><plain>Of these patients, 155 had predominant <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo>, 24 had significant <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo>, and the remaining 81 with xenograft mitral valve replacement developed valvular dysfunction (25 resulted in predominant <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> and 56 in significant <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were detected in 38 patients (group A) and absent in 222 (group B) </plain></SENT>
<SENT sid="5" pm="."><plain>Group A patients had a higher frequency of recent (less than or equal to 1 week before TEE study) and remote (greater than 1 week before) embolization than did group B patients (recent: 26.3 vs 5.4% [p less than 0.001]; remote: 18.4 vs 5.0% [p less than 0.01]) </plain></SENT>
<SENT sid="6" pm="."><plain>The frequency of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> was also greater in group A patients (100 vs 74.3%; p less than 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The exclusion of patients with significant <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> and sinus rhythm had no effect on the association between LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and evidence of previous embolization </plain></SENT>
<SENT sid="8" pm="."><plain>It is concluded that TEE is a convenient diagnostic modality that can be used to identify a subset of patients with <z:e sem="disease" ids="C0264765" disease_type="Disease or Syndrome" abbrv="">rheumatic mitral valve disease</z:e> at high risk for systemic embolization </plain></SENT>
<SENT sid="9" pm="."><plain>Consequently, preventive anticoagulation for possible embolic complications should be more vigorously adhered to in patients with <z:e sem="disease" ids="C0264765" disease_type="Disease or Syndrome" abbrv="">rheumatic mitral valve disease</z:e> and LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
</text></document>